The HECTD3 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line, engineered for targeted disruption of the HECTD3 gene. This polyclonal knockout model enables loss-of-function studies in a well-characterized cancer cell background, providing a versatile tool for investigating the biological roles of HECTD3-mediated ubiquitination and NF-??B signaling. The heterogeneous population recapitulates a range of genetic knockouts, making it suitable for pooled functional assays and bulk biochemical analyses.
The A-549 cell line, isolated from a 58-year-old Caucasian male with lung adenocarcinoma, is a widely employed model for studying lung cancer biology, including tumorigenesis, metastatic progression, and therapeutic response. As an adherent epithelial line, A-549 cells retain key characteristics of NSCLC and are permissive to signal transduction studies, drug sensitivity profiling, and genetic manipulation. Their robust growth and established use in cancer research make them an ideal host for generating knockout models to dissect oncogenic pathways.
HECTD3 encodes an E3 ubiquitin ligase that catalyzes K63-linked polyubiquitination of TNF receptor-associated factor 3 (TRAF3), targeting it for proteasomal degradation and thereby activating the canonical NF-??B pathway. This activation promotes transcription of pro-survival and proliferative genes. Additionally, HECTD3 ubiquitinates the paracaspase MALT1, further amplifying NF-??B signaling downstream of lymphocyte activation and enhancing resistance to apoptotic stimuli. HECTD3 function is stimulated by pro-inflammatory cytokines such as TNF-?? and IL-1?? and is dependent on ubiquitin-conjugating E2 enzymes of the UbcH5 family. Through these interactions, HECTD3 serves as a critical node connecting extracellular signals to transcriptional responses that maintain cell survival, while indirectly suppressing caspase-8 and -9 activation.
In the context of A-549 lung adenocarcinoma cells, HECTD3 contributes to the malignant phenotype by sustaining NF-??B-driven survival and proliferation. Disruption of HECTD3 in these cells provides an essential model for examining how loss of TRAF3 ubiquitination impairs pathway activation and alters cellular sensitivity to apoptotic triggers. This knockout model is particularly valuable for studying mechanisms of chemoresistance, given the role of NF-??B in attenuating cytotoxic drug responses. Researchers can explore HECTD3-dependent survival signaling and its intersection with apoptosis regulation, offering insights into therapeutic vulnerabilities in lung adenocarcinoma and other HECTD3-overexpressing cancers.
Typical applications include biochemical analysis of HECTD3 protein levels and its target TRAF3 by western blotting, assessment of ubiquitination status through immunoprecipitation-based assays, and monitoring NF-??B activation via luciferase reporter constructs or phospho-p65 detection. Functional consequences of HECTD3 loss can be measured by Annexin V apoptosis assays and MTT viability assays, enabling quantification of apoptotic susceptibility and growth inhibition. The knockout cells are also suited for drug sensitivity profiling to identify compounds whose efficacy is enhanced in the absence of HECTD3-mediated survival signaling. These polyclonal cells serve as a robust platform for mechanistic studies and high-throughput screening of HECTD3 inhibitors. For further information or to discuss custom projects, contact Ascent Research.
